midpage
Projects
Sign in to see your projects.
38 F. Supp. 3d 162
D. Mass.
2014
Read the full case

Background

  • Biogen Idee (via Fiers) owns application '843 (filed 1994; divisional to earlier filings); JFCR (via Sugano) owns application '757 (filed 1995). Both claim human fibroblast interferon (hFIF).
  • PTO declared an interference between '843 and '757 on July 16, 2013 (Interference No. 105,939). The PTAB found interference-estoppel based on an earlier 1983 interference (No. 101,096) and finally refused the '843 claims on October 3, 2013.
  • Biogen Idee sued in district court under 35 U.S.C. § 146 and 28 U.S.C. §§ 1331, 1338(a), seeking review of the PTAB decision.
  • Defendants moved to dismiss for lack of personal and subject-matter jurisdiction; plaintiff asked, if the court lacked jurisdiction, that the case be transferred to the Federal Circuit.
  • The legal dispute centers on whether district-court review under pre-AIA § 146 remains available for interferences declared after Sept. 16, 2012, given the AIA, its effective-date provisions, and the AIA Technical Corrections Act (TCA).

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether district court has subject-matter jurisdiction to review PTAB interference decisions declared after Sept. 16, 2012 AIA § 3(n)(1) preserves pre-AIA appeals (including § 146) for pre-AIA patents; therefore district-court review remains available AIA and TCA limited pre-AIA carryover; Congress reinstated pre-AIA § 141 (Federal Circuit) for post‑effective interferences via the TCA but did not preserve § 146 — appeals lie only to the Federal Circuit Court lacks subject-matter jurisdiction; appeals of interferences declared after Sept. 15, 2012 are reviewable only in the Federal Circuit per the TCA and AIA construction
Whether the action should be dismissed or transferred if court lacks jurisdiction Transfer to Federal Circuit under 28 U.S.C. § 1631 is warranted in interest of justice N/A (defendants sought dismissal) Court transfers the action to the U.S. Court of Appeals for the Federal Circuit under § 1631 rather than dismissing

Key Cases Cited

  • Kokkonen v. Guardian Life Ins. Co. of Am., 511 U.S. 375 (statutory grant of jurisdiction required)
  • Chase Manhattan Bank v. S. Acres Dev. Co., 434 U.S. 236 (federal court power is limited to statutory grants)
  • Cipollone v. Liggett Group, Inc., 505 U.S. 504 (expressio unius est exclusio alterius principle)
  • Burlington N. R.R. Co. v. Oklahoma Tax Comm’n, 481 U.S. 454 (legislative history cannot override plain statutory language)
  • In re Teles AG Informationstechnologien, 747 F.3d 1357 (Fed. Cir. 2014) (if district court lacks jurisdiction, transfer under § 1631 is appropriate)
  • Fafel v. DiPaola, 399 F.3d 403 (1st Cir. 2005) (plaintiff bears burden to establish subject-matter jurisdiction)
  • Murphy v. United States, 45 F.3d 520 (1st Cir. 1995) (same)
  • Merlonghi v. United States, 620 F.3d 50 (1st Cir. 2010) (Rule 12(b)(1) standard permitting consideration of evidence outside complaint)
Read the full case

Case Details

Case Name: Biogen Idec MA, Inc. v. Japanese Foundation for Cancer Research
Court Name: District Court, D. Massachusetts
Date Published: May 22, 2014
Citations: 38 F. Supp. 3d 162; 2014 U.S. Dist. LEXIS 70316; 2014 WL 2167677; Civil No. 13-13061-FDS
Docket Number: Civil No. 13-13061-FDS
Court Abbreviation: D. Mass.
Log In